Caribou Biosciences Inc (CRBU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caribou Biosciences Inc (CRBU) has a cash flow conversion efficiency ratio of -0.232x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.79 Million) by net assets ($98.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CRBU market cap overview for the company's overall valuation and market capitalisation.
Caribou Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Caribou Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caribou Biosciences Inc ranked by their cash flow conversion efficiency. See Caribou Biosciences Inc cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cango Inc
NYSE:CANG
|
-0.529x |
|
AOPEN Inc
TW:3046
|
-0.003x |
|
D&D Platform Reit Co Ltd
KO:377190
|
N/A |
|
DaeChang Solution Co. Ltd
KQ:096350
|
-0.002x |
|
Onde SA
WAR:OND
|
-0.205x |
|
Carnarvon Energy Ltd
AU:CVN
|
0.000x |
|
Airtel Africa Plc
LSE:AAF
|
0.286x |
|
De Licacy Industrial Co Ltd
TW:1464
|
0.054x |
Annual Cash Flow Conversion Efficiency for Caribou Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Caribou Biosciences Inc from 2019 to 2025. View CRBU stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $122.17 Million | $-110.99 Million | -0.908x | -66.28% |
| 2024-12-31 | $252.95 Million | $-138.20 Million | -0.546x | -115.75% |
| 2023-12-31 | $368.40 Million | $-93.29 Million | -0.253x | +16.24% |
| 2022-12-31 | $300.87 Million | $-90.97 Million | -0.302x | -260.58% |
| 2021-12-31 | $387.82 Million | $-32.52 Million | -0.084x | -105.92% |
| 2020-12-31 | $-23.44 Million | $-33.22 Million | 1.417x | +133.05% |
| 2019-12-31 | $7.46 Million | $-32.01 Million | -4.289x | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD… Read more